Artificial intelligence R&D to combat age-related diseases

By Flora Southey contact

- Last updated on GMT

Researchers from the University of Copenhagen and Insilico Medicine have teamed up to identify compounds for drug development, using artificial intelligence (AI). 

Baltimore, US-based Insilico will use an AI method known as ‘deep learning’ – where a machine learns the best way to achieve an ‘object recognition task​’ -  to sort data sets for gene expression, and determine which molecules can stimulate DNA repair.

The University will then be in charge of testing the molecules, Insilico’s Qingsong Zhu told Biopharma-Reporter.

“Insilico will make ​in silico predictions and the University of Copenhagen will validate some of the predictions ​in vitro and ​in vivo,” ​explained Zhu.

Drug development

Zhu said he hopes the project will result in drug development to extend healthy human longevity.

“Many of the age-related diseases, such as Alzheimer’s disease, Parkinson disease, cardiovascular disease and aging itself are strongly associated with the decline of DNA repair mechanisms,” ​said Zhu.

The University’s Morten Scheibye-Knudsen also said he hoped the research would benefit older populations.

“If we can find some molecules with the ability to repair our DNA, it is not unthinkable that we can continue to increase the limit on human lifespan,” ​said the University’s Morten Scheibye-Knudsen.

Zhu told us the partners plan to license out the technology to third parties.

Related topics: Bio Developments